Showing results (771-780 of 1,877) with videos related to

Sort By:
Pageof 188
Immunotherapy|November 18, 2020
A review of secukinumab in psoriasis treatmentScott H Berg, Esther A Balogh, Rima I Ghamrawi, et al.
Immunotherapy|October 20, 2020
Killing efficiency affected by mutually modulated PD-1 and PD-L1 expression via NKT-hepatoma cell interactionsLiwei Liu, Mingya Yang, Qia Xu, et al.
Immunotherapy|October 22, 2020
Early change in peripheral CD4+ T cells associated with clinical outcomes of immunotherapy in gastrointestinal cancerChang Liu, Yanni Wang, Shuang Li, et al.
Immunotherapy|January 4, 2023
Antigen-independent tumor targeting by CBX-12 (alphalex™-exatecan) induces long-term antitumor immunitySophia Gayle, Timothy Paradis, Kelli Jones, et al.
Immunotherapy|June 29, 2021
Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse modelsEduardo Huarte, Michael Peel, Ashish Juvekar, et al.
Immunotherapy|June 29, 2021
Urothelial carcinoma in the era of immune checkpoint inhibitorsNadine Khalife, Claude Chahine, Manal Kordahi, et al.
Immunotherapy|June 23, 2021
Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanomaAhmad A Tarhini, Ila Joshi, Fiona Garner
Immunotherapy|July 7, 2022
Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancerMin Huang, Peter Fasching, Amin Haiderali, et al.
Immunotherapy|January 5, 2021
Acute interstitial nephritis and PR3-ANCA following reintroduction of pembrolizumab: a case reportMatthew Mulroy, Sanaz Ghafouri, Anthony Sisk, et al.
Immunotherapy|January 5, 2021
An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three casesLázaro Manuel Filgueira, Julio Betancourt Cervantes, Orlando Adolfo Lovelle, et al.
Pageof 188